Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 Trial)

Clinical Advances in Hematology and Oncology

Volumn 12, Issue 4, 2014, Pages 6-7

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; AMYLASE; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; ORTERONEL; PREDNISONE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; CONSTIPATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HUMAN; HYPERTENSION; HYPOKALEMIA; MULTICENTER STUDY (TOPIC); NAUSEA AND VOMITING; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); UPREGULATION;

EID: 84922229122     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COUAA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983-992.
2. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138-148.
3. Dreicer R, Maclean D, Suri A, et al. Phase I/II trial of orteronel (TAK-700)-an investigational 17,20-lyase inhibitor-in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2014;20(5):1335-1344.
4. Dreicer R, Jones R, Oudard S, et al. Results from a phase 3, randomized, double-blind, multicenter, placebocontrolled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial) [ASCO GU abstract 7]. J Clin Oncol. 2014;32(4)(suppl).
5. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7):1148-1159.